It is also worth noting that cancer cells are capable of increasing PD-L1 expression in response to a robust immune attack that is usually mounted by tumor antigen-specific T cells, and this process is largely dependent on effective immune recognition, which in turn, is dependent on increased somatic mutation and neoantigen burden [20]. This evidence concerns the gene CD274 and neoplasm.